Bone Metastases from Prostate Cancer

Francesco Bertoldo, MD, is Associate Professor of Internal Medicine at the School of Medicine, University of Verona, Italy. Since 2003 he has been Chief of Bone and Mineral Metabolism Diseases and the Osteo-oncology Unit in the Department of Medicine, University Hospital GB Rossi, Verona, Italy. Dr. Bertoldo is a member of the Directive Council of the Italian Society of Osteoporosis and Bone Diseases (SIOMMMS) and of the Italian Society of Osteo-oncology. Since 2009 he has been a member of the Guidelines Committee of the Italian Association of Medical Oncology (AIOM) and SIOMMMS. In 2011 he served as coordinator of the Guidelines for Bone Disease in Prostate Cancer produced by the Italian Society of Urology. He has published more than 100 papers in national and international journals in the field of metabolic and cancer-related bone diseases.Francesco Boccardo graduated cum laude in 1975 from the Medical School of the University of Genoa, Italy, where he then specialized in Oncology. He started his professional career in 1977 at the National Cancer Institute in Genoa and is now Director of the Academic Unit of Medical Oncology at the Institute. In 1998 he was appointed Full Professor of Medical Oncology at the Medical School of the University of Genoa, Italy, where, since 2001 he has been Director of the Postgraduate Medical School in Medical Oncology. Dr. Boccardo has served as President of the Italian Association of Medical Oncology (AIOM) and was one of the founders of the Italian Society of Urologic Oncology (SIURO).Emilio Bombardieri, MD, is a specialist in Nuclear Medicine, Oncology, and Sports Medicine who is currently Clinical Scientific Director of Nuclear Medicine at the Humanitas Gavazzeni Hospital, Bergamo, Italy. In a long career he became Director of the Nuclear Medicine Division of the Istituto Nazionale Tumori, Milan in 1994 and Director of the Department of Diagnostic Imaging and Radiotherapy atthe Institute in 2007. Since 1982 he has been Professor of Physiology and Endocrinology at the Catholic University, ISEF, Milan. Dr. Bombardieri has served as President of the Italian Association of Nuclear Medicine (AIMN), has chaired the EANM (European Association of Nuclear Medicine) Oncology Committee, and was nominated President of the EANM Congress 2012 in Milan. He has published more than 400 papers in national and international journals, and several scientific textbooks in Diagnostic Imaging and Oncology.Laura Evangelista, MD, PhD, is a nuclear medicine physician at Veneto Institute of Oncology IOV – IRCCS, Padua, Italy. Following a residency in Nuclear Medicine at University “Federico II” of Napoli, Italy, she worked as a research fellow at the University “Federico II” of Napoli, the Memorial Sloan Kettering Hospital, New York City, and the Mayo Clinic of Rochester, USA, focusing on PET/CT in breast cancer, prostate cancer, and other oncological diseases.She is a member of the Translational and Molecular Imaging Committee for the European Association of Nuclear Medicine. She has published about 100 papers in national and international journals in the field of nuclear medicine.Riccardo Valdagni has been Head of the Oncologic Radiotherapy Unit at the National Cancer Institute in Milan since 2011 and Head of the Prostate Program since 2003. Since 2009 he has been Vice President of the Italian Society of Oncologic Urology (SIUrO) and in 2010 he became a member of the Steering Committee of the multicenter international active surveillance protocol PRIAS (Prostate Cancer Research International: Active Surveillance). Dr. Valdagni is dedicated to the development of an integrated and multidisciplinary approach to prostate cancer. He has always been interested in psychology and psycho-oncology, and is a professor at the Il Ruolo Terapeutico psychoanalytic therapy center. He is the author of many internationalscientific publications in the field of Oncology.

“This is a very interesting book centered on bone metastases from prostate cancer, edited and authored by a multidisciplinary team with specific experience in the field. … The interest of the book increases because many new tools have recently been added to the diagnostic and therapeutic paraphernalia, giving hope also to patients surviving with a very bad quality of life and with a rapidly negative fate.” (Luigi Mansi, European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, 2019)​

• Biology and pathophysiology of bone metastases.- Markers of bone turnover.- Bone homing and metastasis.- Markers of prostate cancer.- Circulating cells.- Radiological assessment of bone metastases.- Nuclear Medicine: bone target imaging.- Nuclear Medicine: cancer and receptor target imaging.- Hormonal therapy.- Chemotherapy .- Combinations of hormonal therapy and chemotherapy.- Surgery.- Radiotherapy.- Bone-targeted agents.- Bone seeking radionuclide for therapy.- New frontiers in treatments.- Approaches for the assessment of response to therapies.- From Symptom control to pain palliation.- Economic impact of prostate cancer bone metastases.- Multidisciplinary approach.